Spotlight Therapeutics
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3953 Point Eden Way, Hayward, California...Phone Number
(510) 284-4799Website
www.spotlighttx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Spotlight Therapeutics
Established in mid-2018, Spotlight Therapeutics is a privately held biotechnology company advancing a pipeline of cell-targeted in vivo CRISPR gene editing therapies. Spotlight's proprietary technology platform TAGE (Targeted Active Gene Editors) is a new class of biologics, CRISPR effectors engineered for direct delivery in vivo, to achieve cell-selective therapeutic genome editing. Spotlight's pipeline is advancing its modular programmable CRISPR effectors towards clinical studies in immuno-oncology, ophthalmic diseases and hemoglobinopathies. The company is headquartered in Hayward, California.Explore more
Spotlight Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Spotlight Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Spotlight Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Spotlight Therapeutics
Check out if Spotlight Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Spotlight Therapeutics had a recent Job posting/layoffs
Check if Spotlight Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Spotlight Therapeutics has new funding data
Spotlight Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Spotlight Therapeutics recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Spotlight Therapeutics
Compare insights from companies similar to Spotlight Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Spotlight Therapeutics
<$5M
11-50
Private
$66.5M
2018
MK
Mark KnuthSenior Director and Research Fellow, Platform Technologies
Company Profile Activity
Activity Insights
Spotlight Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Spotlight Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Spotlight Therapeutics.
Spotlight Therapeutics financials insights
Gather financial insights about Spotlight Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$30M
2022
Series B
$36.5M
Spotlight Therapeutics Tech Stack
A closer look at the technologies used by Spotlight Therapeutics
Most Recent Scoops
Layoffs
Layoffs
Funding
Project
Medical Research, Clinical Operations, Operations
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Spotlight Therapeutics News & Media
Spotlight Therapeutics Appoints Visionary Global Pharma Drug Developer Antoine Yver, M.D., M.Sc. as First Independent Board Member
SAN FRANCISCO--(BUSINESS WIRE)--Spotlight Therapeutics, Inc. (“Spotlight”), a biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene editing biologics, today announced the appointment of Antoine Yver, M.D., M.Sc. to the Spotlight Board of Directors. Trained as an oncologist and immunologist, Dr. Yver’s extensive industry experience and perceptive acumen will be extremely valuable as Spotlight continues to strengthen its highly differentiated TAGE (Targeted ActiSpotlight Therapeutics Raises $36.5 Million Series B to Advance a Pipeline of Cell-Targeted In Vivo CRISPR Gene Editing Biologics
SAN FRANCISCO--(BUSINESS WIRE)--Spotlight Therapeutics, Inc. (“Spotlight”), a biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene editing biologics, today announced a $36.5M Series B financing to fuel a drive toward the clinic. The financing round was co-led by new investors GordonMD Global Investments and EPIQ Capital Group, with participation from Magnetic Ventures, as well as existing investors GV (formerly Google Ventures) and Emerson Collective and otheSpotlight raises $30 million for CRISPR
Spotlight Therapeutics has raised $30 million in series A financing to develop CRISPR gene-editing therapies for genetic blood diseases and cancer. Spotlight attaches antibodies, cell-penetrating peptides, or ligands to a CRISPR ribonucleoprotein—a guide RNA paired with a nuclease like Cas9—to shuttle the gene-editing system to particular cells in the body. Other CRISPR firms rely on lipid nanoparticles or viral vectors for delivery. The start-up was quietly cofounded in 2018 by gene-editing sciSpotlight Therapeutics Closes $30M Series A Led by GV to Advance Pipeline of Non-viral CRISPR Gene Editing Biologics
SAN FRANCISCO--(BUSINESS WIRE)-- #CRISPR--Spotlight Therapeutics, Inc., a biotechnology company developing non-viral gene editing therapeutics for direct in vivo editing of target genes, closed its Series A financing bringing the total raised to $30 million. The financing was led by GV, formerly Google Ventures, with participation from additional undisclosed investors. Realizing the full revolutionary potential of CRISPR genome editing requires the ability to edit target genes directly in the ri
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Spotlight Therapeutics
Sign Up For FreeTo access detailed company insights
Established in mid-2018, Spotlight Therapeutics is a privately held biotechnology company advancing a pipeline of cell-targeted in vivo CRISPR gene editing therapies. Spotlight's proprietary technology platform TAGE (Targeted Active Gene Editors) is a new class of biologics, CRISPR effectors engineered for direct delivery in vivo, to achieve cell-s... Read More
